{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:47:22Z","timestamp":1788835642864,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Vaccines Institute for Global Health (NVGH)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jpba.2017.02.042","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T03:04:28Z","timestamp":1487905468000},"page":"143-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever"],"prefix":"10.1016","volume":"139","author":[{"given":"C.","family":"Giannelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cappelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arcuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Di Cioccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Saul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Micoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.02.042_bib0005","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"Lancet Global Health."},{"issue":"Suppl. 1","key":"10.1016\/j.jpba.2017.02.042_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00063030-200115001-00002","article-title":"Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration","volume":"15","author":"Lebacq","year":"2001","journal-title":"BioDrugs"},{"key":"10.1016\/j.jpba.2017.02.042_bib0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1586\/14760584.2013.845529","article-title":"Development of Vi conjugate \u2013 a new generation of typhoid vaccine","volume":"12","author":"Szu","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jpba.2017.02.042_bib0020","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jpba.2017.02.042_bib0025","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.vaccine.2011.11.108","article-title":"Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi","volume":"30","author":"Micoli","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jpba.2017.02.042_bib0030","doi-asserted-by":"crossref","first-page":"e25398","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new Vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"van Damme","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2017.02.042_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jpba.2017.02.042_bib0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0264-410X(92)90046-M","article-title":"Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide\u2013protein conjugate vaccine is decreased by admixture of high doses of free saccharide","volume":"10","author":"Peeters","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.jpba.2017.02.042_bib0045","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0264-410X(98)00129-7","article-title":"Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response","volume":"16","author":"Rodriguez","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.jpba.2017.02.042_bib0050","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/CVI.00387-10","article-title":"Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi","volume":"18","author":"Rondini","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jpba.2017.02.042_bib0055","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.vaccine.2011.12.046","article-title":"Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine","volume":"30","author":"An","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jpba.2017.02.042_bib0060","unstructured":"WHO Guidelines on the quality, safety and efficacy of typhoid conjugate vaccines: 2013."},{"key":"10.1016\/j.jpba.2017.02.042_bib0065","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.65.6.2088-2093.1997","article-title":"Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker","volume":"65","author":"Kossaczka","year":"1997","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jpba.2017.02.042_bib0070","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1016\/j.vaccine.2011.08.019","article-title":"Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity","volume":"29","author":"An","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jpba.2017.02.042_bib0075","first-page":"259","article-title":"Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines","volume":"103","author":"Lei","year":"2000","journal-title":"Dev. Biol."},{"key":"10.1016\/j.jpba.2017.02.042_bib0080","first-page":"251","article-title":"Capillary electrophoretic analysis of meningococcal polysaccharide-diphtheria toxoid conjugate vaccines","volume":"103","author":"Lamb","year":"2000","journal-title":"Dev. Biol."},{"key":"10.1016\/j.jpba.2017.02.042_bib0085","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1002\/elps.201300298","article-title":"Single validation of CE method for determining free polysaccharide content in a Brazilian meningococcal C conjugate vaccine","volume":"34","author":"Medeiros de Souza","year":"2013","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jpba.2017.02.042_bib0090","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/S0264-410X(02)00183-4","article-title":"Development of a high-performance anion-exchange chromatography with pulsed-amperometric detection based quantification assay for pneumococcal polysaccharides and conjugates","volume":"20","author":"Talaga","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jpba.2017.02.042_bib0095","unstructured":"A. Bardotti, S. Ricci, D. Proietti, Separation of unconjugated and conjugated saccharide by solid phase extraction, WO\/2005\/090985."},{"key":"10.1016\/j.jpba.2017.02.042_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/bc00031a015","article-title":"Mechanism of amide formation by carbodiimide for bioconjugation. in aqueous media","volume":"6","author":"Nakajima","year":"1995","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.jpba.2017.02.042_bib0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jpba.2017.02.042_bib0110","doi-asserted-by":"crossref","first-page":"e72588","DOI":"10.1371\/journal.pone.0072588","article-title":"Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness","volume":"8","author":"Bjarnarson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2017.02.042_bib0115","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J. Infect. Dis."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516312511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516312511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T21:25:05Z","timestamp":1601673905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516312511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":23,"alternative-id":["S0731708516312511"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.042","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}